Arbutus Biopharma
ABUS
Arbutus Biopharma (ABUS) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- $0.01
- EPS estimate
- −$0.05
- EPS surprise
- +121.05%
- Revenue surprise
- +574.98%
- Revenue
- $10.7M
- Revenue estimate
- $1.6M
- Reported
- Aug 6, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 6, 2025 | −$0.05 | $0.01 | +121.05% | $10.7M | SEC |
| Q1 2025 | May 14, 2025 | −$0.10 | −$0.13 | −25.00% | $1.8M | SEC |
| Q4 2024 | Mar 27, 2025 | −$0.08 | −$0.07 | +12.50% | $1.6M | SEC |
| Q3 2024 | Nov 6, 2024 | −$0.09 | −$0.10 | −6.38% | $1.3M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.10 | −$0.11 | −14.58% | $1.7M | SEC |
| Q1 2024 | May 2, 2024 | −$0.11 | −$0.10 | +9.09% | $1.5M | SEC |
| Q4 2023 | Feb 29, 2024 | −$0.12 | −$0.12 | −3.45% | $2.1M | SEC |
| Q3 2023 | Nov 7, 2023 | −$0.11 | −$0.12 | −7.14% | $4.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.11 | −$0.10 | +10.71% | $4.7M | SEC |
| Q1 2023 | May 4, 2023 | −$0.14 | −$0.10 | +26.47% | $6.7M | SEC |
| Q4 2022 | Mar 2, 2023 | −$0.13 | −$0.13 | +2.99% | $6.2M | SEC |
| Q3 2022 | Nov 9, 2022 | −$0.13 | −$0.12 | +6.25% | $6.0M | — |
| Q2 2022 | Aug 4, 2022 | −$0.12 | −$0.10 | +19.35% | $14.2M | — |
| Q1 2022 | May 5, 2022 | −$0.16 | −$0.11 | +31.25% | $12.6M | — |
| Q4 2021 | Mar 3, 2022 | −$0.19 | −$0.15 | +21.05% | $3.2M | — |
| Q3 2021 | Nov 4, 2021 | −$0.24 | −$0.24 | −0.84% | $3.3M | — |
| Q2 2021 | Aug 5, 2021 | −$0.23 | −$0.23 | −2.22% | $2.3M | — |
| Q1 2021 | May 5, 2021 | −$0.23 | −$0.21 | +9.25% | $2.1M | — |
| Q4 2020 | Mar 4, 2021 | −$0.22 | −$0.23 | −3.88% | $2.4M | — |
| Q3 2020 | Nov 5, 2020 | −$0.22 | −$0.27 | −25.00% | $1.5M | — |
Quarterly revenue
Frequently asked questions
When did Arbutus Biopharma (ABUS) last report earnings?
Arbutus Biopharma last reported on Aug 6, 2025, covering fiscal Q2 2025.
Did ABUS beat earnings estimates?
Yes. Arbutus Biopharma reported EPS of $0.01 for Q2 2025 against a −$0.05 estimate — a 121.05% beat.
How much revenue did ABUS report last quarter?
Arbutus Biopharma reported $10.7M in revenue for Q2 2025, against a consensus estimate of $1.6M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.